{rfName}
Co

Indexed in

License and use

Citations

6

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Vera Mendoza, Maria IsabelAuthor

Share

June 9, 2021
Publications
>
Article
Diamond

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

Publicated to:REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 113 (3): 170-178 - 2021-01-01 113(3), DOI: 10.17235/reed.2020.6847/2019

Authors: Martínez Lozano, Helena; Miranda Bautista, J; González Lama, Yago; Carpio López, Daniel; Barreiro de Acosta, Manuel; Pérez Calle, José Lázaro; Relea Pérez, Lucía; Villa, Keyla; Matallana, Virginia; Calvo, Marta; Vera Mendoza, María Isabel; Pérez Galindo, Pablo; Mora Cuadrado, Natalia; López Serrano, Pilar; Marín Jiménez, Ignacio; Menchén, Luis Alberto

Affiliations

Complejo Hospitalario de Pontevedra - Author
Complejo Hospitalario Universitario de Santiago - Author
Complexo Hospitalario Universitario A Coruña - Author
Hospital General Universitario Gregorio Marañón - Author
Hospital Universitario Fundación Alcorcón - Author
Hospital Universitario Puerta de Hierro Majadahonda - Author
See more

Abstract

biosimilar infliximab (CTP-13) has been recently approved for the treatment of several immune-mediated inflammatory disorders, including inflammatory bowel disease (IBD). Comparative studies between this biosimilar and original infliximab in the real clinical practice are scarce. The objective of this study was to compare short and long-term safety and efficacy of original (O) and biosimilar infliximab (B-IFX) in biologic-naïve, IBD patients in the real life clinical practice.a retrospective, multicentric study was performed in five Spanish hospitals. Consecutive IBD, biologic-naïve patients from an historic cohort who initiated O-IFX from January 2013 were compared with biologic-naïve patients, who started treatment with B-IFX since its approval in January 2015. The evaluation of efficacy was assessed after the induction phase, at week 14 and week 54 of treatment. Time to dose escalation or treatment persistence of both O-IFX and B-IFX was also considered. The appearance of serious adverse events was recorded.two hundred and thirty-nine IBD biologic-naïve patients who started with O-IFX or B-IFX were included: 153 patients were diagnosed with Crohn's disease (95 treated with O- and 58 treated with B-IFX) and 86 with ulcerative colitis (40 received O- and 46 received B-IFX). At weeks 14 and 54, both O-IFX and B-IFX groups reached a similar clinical response and remission rates. Time to dose escalation, treatment persistence and safety profile were comparable between both groups.this long-term real-life experience provides additional evidence of the similarity of O- and B-IFX CTP-13 in terms of efficacy and safety in IBD patients.

Keywords

BiodiversidadeCiências biológicas iiFarmaciaGastroenterologyGastroenterology & hepatologyGeneral medicineMedicina iMedicina iiMedicina iiiMedicine (miscellaneous)Odontología

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Gastroenterology & Hepatology, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.14, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

  • WoS: 2
  • Open Alex: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-18:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 34.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 35 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.5.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Ensure healthy lives and promote well-being for all at all ages, with a probability of 41% according to the mBERT algorithm developed by Aurora University.